Skip to main content

Advertisement

SpringerLink
Log in

Liver-Directed Therapies for Neuroendocrine Neoplasms

  • Neuroendocrine Neoplasms (NS Reed, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To comprehensively synthesise and appraise the available evidence regarding therapies for metastatic neuroendocrine neoplasms that exploit the hepatic vasculature to deliver therapy to liver metastases.

Recent Findings

Various techniques including transarterial embolisation/chemoembolisation (TAE/TACE) and selective internal radiotherapy (SIRT, also termed radioembolisation [RE]) have been examined in patents with neuroendocrine liver metastases. Variations in the radioactive agents for selective internal radiotherapy (SIRT) have been explored, such as the use of Holmium-166, in addition to more established agents such as Yttrium-90. Recent trials have examined the safety and efficacy of combining liver-targeted therapy with systemic treatments, such as peptide receptor radionuclide therapy.

Summary

More retrospective case series of liver-directed modalities will not provide additional knowledge. Randomised clinical trials have begun to compare the efficacy of different forms of liver-directed therapies, and also their combination with systemic treatment. Their results are expected to guide optimal treatment sequencing within multimodal concepts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105:2563–9.

    Article  PubMed  Google Scholar 

  2. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3:1335.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Clift AK, Kidd M, Bodei L, Toumpanakis C, Baum RP, Oberg K, et al. Neuroendocrine neoplasms of the small bowel and pancreas. Neuroendocrinology. 2020;110(6):444–76.

    Article  CAS  PubMed  Google Scholar 

  4. Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–85.

    Article  CAS  PubMed  Google Scholar 

  5. Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer. 2015;121(8):1172–86.

    Article  CAS  PubMed  Google Scholar 

  6. Frilling A, Li J, Malamutmann E, Schmid K-W, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009;96:175–84.

    Article  CAS  PubMed  Google Scholar 

  7. Frilling A, Clift AK. Surgical approaches to the management of neuroendocrine liver metastases. Endocrinol Metab Clin N Am. 2018;47(3):627–43.

    Article  Google Scholar 

  8. Saxena A, Chua TC, Perera M, Chu F, Morris DL. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol. 2012;21:e131–41.

    Article  PubMed  Google Scholar 

  9. Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P, et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015;17:29–37.

    Article  Google Scholar 

  10. Spolverato G, Bagante F, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, et al. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: an international multi-institutional analysis. J Surg Oncol. 2017;116:298–306.

    Article  CAS  PubMed  Google Scholar 

  11. Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844–60.

    Article  CAS  PubMed  Google Scholar 

  12. Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors. Pancreas. 2010;39:753–66.

    Article  PubMed  Google Scholar 

  13. Woltering EA, Wright AE, Stevens MA, Wang YZ, Boudreaux JP, Mamikunian G, et al. Development of effective prophylaxis against intraoperative carcinoid crisis. J Clin Anesth. 2016;32:189–93.

    Article  CAS  PubMed  Google Scholar 

  14. Ronot M, Clift AK, Baum RP, Singh A, Kulkarni HR, Frilling A, et al. Morphological and functional imaging for detecting and assessing the resectability of neuroendocrine liver metastases. Neuroendocrinology. 2018;106(1):74–88.

    Article  CAS  PubMed  Google Scholar 

  15. Loewe C, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. Am J Roentgenol. 2003;180:1379–84.

    Article  Google Scholar 

  16. . Grozinsky-Glasberg S, Kaltsas G, Kaltsatou M, Lev-Cohain N, Klimov A, Vergadis V, et al. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice. Endocrine. 2018;60:499–509 Retrospective comparison of different forms of liver-directed therapy for neuroendocrine liver metastases, which should be followed by prospective studies.

    Article  CAS  PubMed  Google Scholar 

  17. Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. Am J Clin Oncol. 2012;35:393–8.

    Article  PubMed  Google Scholar 

  18. Kanabar R, Barriuso J, McNamara MG, Mansoor W, Hubner RA, Valle JW, et al. Liver embolisation for patients with neuroendocrine neoplasms: systematic review. Neuroendocrinology. 2020. https://doi.org/10.1159/000507194This recent systematic review provides a synthesis of several liver-directed therapies for metastatic neuroendocrine neoplasms, including results of symptomatic control.

  19. de Mestier L, Zappa M, Hentic O, Vilgrain V, Ruszniewski P. Liver transarterial embolizations in metastatic neuroendocrine tumors. Rev Endocr Metab Disord. 2017;18:459–71.

    Article  PubMed  Google Scholar 

  20. Zener R, Yoon H, Ziv E, Covey A, Brown KT, Sofocleous CT, et al. Outcomes after transarterial embolization of neuroendocrine tumor liver metastases using spherical particles of different sizes. Cardiovasc Intervent Radiol. 2019;42:569–76.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Chen JX, Rose S, White SB, et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Intervent Radiol. 2017;40:69–80.

    Article  PubMed  Google Scholar 

  22. Egger ME, Armstrong E, Martin RC, Scoggins CR, Philips P, Shah M, et al. Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis. J Am Coll Surg. 2020;230(4):363–70.

    Article  PubMed  Google Scholar 

  23. Do Minh D, Chapiro J, Gorodetski B, et al. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol. 2017;27:4995–5005.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Fiore F, Del Prete M, Franco R, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47:177–82.

    Article  CAS  PubMed  Google Scholar 

  25. Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol. 2013;36:449–59.

    Article  PubMed  Google Scholar 

  26. Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, et al. A phase ii clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012;23:2335–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Prince JF, Van Den Bosch MAAJ, Nijsen JFW, et al. Efficacy of radioembolization with 166Ho-microspheres in salvage patients with liver metastases: A phase 2 study. J Nucl Med. 2018;59:582–8.

    Article  CAS  PubMed  Google Scholar 

  28. Kalinowski M, Dressler M, Konig A, El-Sheik M, Rinke A, Hoffken H, et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion. 2009;79:137–42.

    Article  PubMed  Google Scholar 

  29. Yang TX, Chua TC, Morris DL. Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases – a systematic review. Surg Oncol. 2012;21:299–308.

    Article  PubMed  Google Scholar 

  30. Frilling A, Clift AK, AJAT B, Alsafi A, Wasan HS, Al-Nahhas A, et al. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. HPB. 2019;21(7):773–83 A comprehensive recent systematic review and meta-analysis of clinical outcomes (objective response rate and disease control rate) from retrospectve case series. The study notes that currently available retrospective evidence is sufficient to establish the potential of the approach, and advocates for prospective studies.

  31. Singla S, LeVea CM, Pokuri VK, Attwood KM, Wach MM, Tomaszewski GM, et al. Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience. J Gastrointest Oncol. 2016;7:441–8.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Barbier CE, Garske-Román U, Sandström M, Nyman R, Granberg D. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging. 2016;43:1425–31.

    Article  CAS  PubMed  Google Scholar 

  33. Peker A, Çiçek O, Soydal Ç, Küçük NÖ, Bilgiç S. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Diagn Interv Radiol. 2015;21:54–9.

    Article  PubMed  Google Scholar 

  34. Braat AJAT, Kappadath SC, Ahmadzadehfar H, et al. Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. Cardiovasc Intervent Radiol. 2019;42:413–25 This large, multi-centre study presents important evidence on radioembolsation’s safety and efficacy from specialist centres.

  35. Ezziddin S, Meyer C, Kahancova S, Haslerud T, Willinek W, Wilhelm K, et al. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53:1663–9.

    Article  CAS  PubMed  Google Scholar 

  36. Koay EJ, Owen D, Das P. Radiation-induced liver disease and modern radiotherapy. Semin Radiat Oncol. 2018;28:321–31.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Su Y-K, Mackey RV, Riaz A, Gates VL, Benson AB, Miller FH, et al. Long-term hepatotoxicity of Yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver. J Vasc Interv Radiol. 2017;28:1520–6.

    Article  PubMed  Google Scholar 

  38. Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018;19:390 Importantly, this protocol outlines a current trial, which should be of key interest for practitioners in this field.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Braat AJAT, Bruijnen RCG, van Rooij R, et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 2020;21:561–70 This important trial is the first of its kind to examine the outcomes of attempting 'radiation boosting' to liver metastases from neuroendocrine neoplams with a combination approach, rather than examining the effects of a liver-directed modality in isolation.

    Article  CAS  PubMed  Google Scholar 

  40. Frilling A, Clift AK. Combining radiolabelled therapies for neuroendocrine neoplasms. Nat Rev Endocrinol. 2020;16:347–8.

    Article  PubMed  Google Scholar 

  41. Kim HS, Shaib WL, Zhang C, Nagaraju GP, Wu C, Alese OB, et al. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. Cancer. 2018;124:1992–2000.

    Article  CAS  PubMed  Google Scholar 

  42. Elf A-K, Andersson M, Henrikson O, Jalnefjord O, Ljungberg M, Svensson J, et al. Radioembolization versus bland embolization for hepatic metastases from small intestinal neuroendocrine tumors: short-term results of a randomized clinical trial. World J Surg. 2018;42(2):506–13.

    Article  PubMed  Google Scholar 

  43. Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287:1050–8.

    Article  PubMed  Google Scholar 

  44. Vouche M, Lewandowski RJ, Atassi R, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59:1029–36.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Braat MNGJA, Samim M, van den Bosch MAAJ, Lam MGEH. The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Transl Imaging. 2016;4:283–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33.

    Article  PubMed  Google Scholar 

  48. Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13.

    Article  CAS  PubMed  Google Scholar 

  49. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Hur S, Chung JW, Kim HC, Oh DY, Lee SH, Bang YJ, et al. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. J Vasc Interv Radiol. 2013;24:947–56.

    Article  PubMed  Google Scholar 

  51. Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao Y, Sohn JH, et al. Imaging biomarkers of tumor response in neuroendocrine liver metastases treated with transarterial chemoembolization: can enhancing tumor burden of the whole liver help predict patient survival? Radiology. 2017;283:883–94.

    Article  PubMed  Google Scholar 

  52. Strosberg D, Schneider EB, Onesti J, Saunders N, Konda B, Shah M, et al. Prognostic impact of serum pancreastatin following chemoembolization for neuroendocrine tumors. Ann Surg Oncol. 2018;25:3613–20.

    Article  PubMed  Google Scholar 

  53. Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys. 2012;83:887–94.

    Article  PubMed  Google Scholar 

  54. Ludwig JM, Ambinder EM, Ghodadra A, Xing M, Prajapati HJ, Kim HS. Lung Shunt Fraction prior to Yttrium-90 radioembolization predicts survival in patients with neuroendocrine liver metastases: single-center prospective analysis. Cardiovasc Intervent Radiol. 2016;39:1007–14.

    Article  PubMed  Google Scholar 

  55. Modlin IM, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: from monoanalytes to transcripts and algorithms. Best Pract Res Clin Endocrinol Metab. 2016;30:59–77.

    Article  CAS  PubMed  Google Scholar 

  56. Barabasch A, Heinzel A, Bruners P, Kraemer NA, Kuhl CK. Diffusion-weighted MRI Is superior to PET/CT in predicting survival of patients undergoing 90 Y radioembolization of hepatic metastases. Radiology. 2018;288:764–73.

    Article  PubMed  Google Scholar 

  57. Mantry PS, Mehta A, Madani B, Mejia A, Shahin I. Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol. 2017;8:799–807.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. BMJ. 2015. https://doi.org/10.1136/bmj.g7594.

Download references

Author information

Authors and Affiliations

  1. CRUK Oxford Centre, University of Oxford, Oxford, UK

    Ashley Kieran Clift

  2. Department of Surgery & Cancer, Imperial College London, London, UK

    Ashley Kieran Clift & Andrea Frilling

  3. Department of Surgery and Cancer, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK

    Andrea Frilling

Authors
  1. Ashley Kieran Clift
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Frilling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Frilling.

Ethics declarations

Conflict of Interest

The authors declare no conflict of interest

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neuroendocrine Neoplasms

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Clift, A.K., Frilling, A. Liver-Directed Therapies for Neuroendocrine Neoplasms. Curr Oncol Rep 23, 44 (2021). https://doi.org/10.1007/s11912-021-01030-0

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11912-021-01030-0

Keywords

Search

Navigation